Immune Shield

Thymosin Alpha-1 + LL-37 + KPV — broad-spectrum immune priming, antimicrobial defence, and inflammation regulation

Thymosin Alpha-1 activates plasmacytoid dendritic cells and promotes Th1/Treg polarisation — it is licensed in 37 countries for HBV/HCV and is under study for COVID-19 and cancer immunotherapy. LL-37 provides innate immune defence via membrane disruption and immunomodulation. KPV targets the MC1/3/5 receptors and NF-κB independently to resolve inflammation. Three immune layers: adaptive priming, innate killing, resolution.

For research purposes only. Not for human consumption.